In particular, CD38 expression in erythrocytes of patients with colorectal, gastric, pancreatic, and breast cancer was found to be significantly higher, with strong correlations to clinical factors such as CEA values, tumor stage, disease progression, lesion site, and degree of anemia. This evidence concerns the gene CD38 and neoplasm.